Terminal › Stocks › TPST

Tempest Therapeutics, Inc. (TPST) Stock

Healthcare · Biotechnology · US

$2.12 +34.18%

Last updated Jun 18, 2026 23:50 UTC

TPST Key Statistics

Market Cap$9.41M

P/E (TTM)-0.31

P/S (TTM)—

P/B (TTM)1.32

Revenue (TTM)$0.00

EPS (TTM)$-6.84

Dividend Yield—

ROE (TTM)-309.60%

Net Margin0.00%

Gross Margin0.00%

52W High$2.47

52W Low$1.50

Analyst ViewBuy

Price Target—

Employees24

Volume1,171,442

About Tempest Therapeutics, Inc.

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.

CEO: Matthew Angel. Company website

See TPST live in QFI Terminal

Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.

Open TPST in Terminal See plans

More Healthcare stocks

UNH UnitedHealth Group Incorporated CVS CVS Health Corporation MCK McKesson Corporation COR Cencora, Inc. NVO Novo Nordisk A/S CI Cigna Corporation CAH Cardinal Health, Inc. ELV Elevance Health Inc.